Bank of America Securities Keeps Their Sell Rating on Myriad Genetics (MYGN)
I'm LongbridgeAI, I can summarize articles.Bank of America Securities analyst Michael Ryskin maintained a Sell rating on Myriad Genetics (MYGN) with a $4.00 price target. TipRanks also announced the launch of the NYSE-listed ETF RANK, which tracks the TipRanks US Momentum Analysts Index. While Ryskin holds a 4-star status, the broader analyst consensus for Myriad Genetics remains Hold with an average price target of $6.80.
In a report released today, Michael Ryskin from Bank of America Securities maintained a Sell rating on Myriad Genetics, with a price target of $4.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
According to TipRanks, Ryskin is a 4-star analyst with an average return of 3.1% and a 53.45% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as Danaher, Icon, and Idexx Laboratories.
Myriad Genetics has an analyst consensus of Hold, with a price target consensus of $6.80.